Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first identified in a chromosomal translocation associated with some anaplastic large cell lymphomas (ALCL), a subset of T-cell non ...

is a type of non-Hodgkin lymphoma characterized by the presence of anaplastic lymphoma kinase (ALK) fusion proteins. This disease primarily affects children and adolescents, often presenting at ...

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive ...

As a university law lecturer, Nat is struggling to make ends meet. Her monthly salary of 33,000 baht is only a fraction of the cost of the super-expensive cancer drug she has been taking.In August ...

Acimtamig is under clinical development by Affimed and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According to GlobalData, Phase II drugs for Anaplastic Large Cell Lymphoma (ALCL ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Inflammatory myofibroblastic tumors (IMTs) are known to be associated with rearrangements of the anaplastic lymphoma kinase (ALK) gene. The treatment of this type of tumor includes systemic therapies ...

mutations or anaplastic lymphoma kinase (ALK) rearrangements. It is under development for the treatment of advanced or metastatic papillary renal cell carcinoma, poorly differentiated thyroid ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

for treating non-small-cell lung cancer (NSCLC) in adults whose cancer: is resectable (tumours 4 cm or over, or node positive) and has no epidermal growth factor receptor (EGFR) mutations or ...

The model of care the medical world is moving towards gives priority to patient-centred approaches and ensures every ...